Lung Cancer Clinical Trial
Computed Tomography (CT) Perfusion Imaging of Lung Cancer
Summary
This is an experimental study of the feasibility and efficacy of CT perfusion (CTP) imaging (CT blood flow measurements) in subjects with non-small cell lung cancer.
Full Description
Drug/Device Information
1) Contrast
30 cc bolus of a low osmolar, iodinated CT contrast agent, which is FDA approved and used in the clinical CT Imaging procedure.
2) Scanner
The 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI) is FDA approved for clinical CT imaging
Research Design and Methods
1) Primary Endpoint
1. Diagnostic yield of tumor perfusion measurements using a contrast assisted computed tomography technique.
2) Secondary Endpoints
Reproducibility of tumor blood flow estimates derived by CT.
Assessment of the association between tumor vascularity responses after two cycles of chemotherapy and subsequent best tumor response according to standard anatomic response evaluation criteria (RECIST).
Predictive value of tumor blood flow for patient survival, compared to the predictive power of tumor size determinations.
Eligibility Criteria
Inclusion Criteria:
Patient with any stage non-small cell lung cancer (NSCLC) who will undergo imaging with CT of the chest with intravenous contrast as standard of care. Other imaging tests will be performed as clinically indicated.
Patient should be receiving, or planning to receive, or have received systemic therapy (chemotherapy and/or novel agents) treatment with or without radiotherapy. Patients should not be receiving adjuvant or postoperative treatment but neoadjuvant treatment is allowed.
Histologically or cytologically proven NSCLC.
At least one measurable primary or other intrathoracic/supraclavicular lesion ≥ 1 cm, according to Response Evaluation Criteria in Solid Tumors (RECIST); this lesion should be either proven to be malignant by biopsy or be considered malignant based on its evolution on previous imaging studies. A scan within 3-6 months prior to registration can be used as the baseline scan.
Age 18 years or older and ability to provide informed consent.
Subjects must use medically appropriate contraception if sexually active; women of childbearing potential must not be pregnant or breastfeeding
Subjects must have normal renal function to participate. Standard laboratory testing to evaluate renal function will be performed prior to administering IV contrast and will be available as standard of care. Renal impairment is defined as a glomerular filtration rate of less than 60 ml/min/1.73 m2 BSA, derived from the patients' serum creatinine concentration.
Exclusion Criteria:
Subjects of reproductive potential, who are sexually active but unwilling and/or unable to use medically appropriate contraception, or women who are pregnant or breastfeeding;
Established allergy to iodine containing contrast media
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Pittsburgh Pennsylvania, 15232, United States
Pittsburgh Pennsylvania, 15232, United States
Pittsburgh Pennsylvania, 15232, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.